Lung cancer test kit PULMOCAN™

oncologyfor precision medicineplasma

Lung cancer has the most established targeted therapy treatment landscape. Targeting specific genetic mutations, such as EGFR and BRAF mutations, ALK, ROS1 and NTRK gene rearrangements with drugs provides specificity towards cancer cells while sparing toxicity to normal cells and ultimately improving patient outcomes. Therefore, genetic testing is a crucial step in matching a patient to the right targeted therapy. Our lung cancer-specific panels can meet all of your clinical needs for lung cancer patients at all disease stages. Optional PD-L1 immunohistochemistry (IHC) test is available to better guide immunotherapy decisions. Targets 139 key genes in lung cancer Guides targeted therapy Evaluates efficacy and toxicity of chemotherapies Identifies potential drug resistance mechanisms Reveals tumor genomic evolution during treatment WHO IS IT FOR Lung cancer patients at different stages of disease seeking precision medicine Lung cancer patients progressed on targeted therapy or systemic treatment Lung cancer patients with recurrent disease after surgery SAMPLE TYPES Tumor tissue (FFPE block/slides, or frozen tissue) Fine needle biopsy Liquid biopsy (plasma and others)